Navigation Links
Enobia Reports Positive Results For Phase II Trial of ENB-0040 in Juvenile Hypophosphatasia
Date:9/24/2010

PRAGUE, Sept. 24 /PRNewswire/ -- Enobia Pharma today announced positive results for its Phase II juvenile clinical trial of ENB-0040 (asfotase alfa), an experimental bone-targeted enzyme replacement therapy intended for the treatment of hypophosphatasia (HPP).  Hypophosphatasia is a rare, inherited, and sometimes fatal metabolic bone disease that affects individuals of all ages. Michael Whyte, MD, Medical/Scientific Director of the Center for Metabolic Bone Disease and Molecular Research at Shriners Hospital for Children in St. Louis, Missouri, and a principal investigator of the Phase II study, presented the findings at the European Society for Paediatric Endocrinology (ESPE) Annual Meeting in Prague. Enobia's abstract describing these Phase II results was awarded the Henning Anderson Prize for best clinical abstract by ESPE.

In this trial, after six months of ENB-0040 treatment results include:

  • Radiographic improvement of rickets
  • Improvement in muscle strength and agility over baseline, including an average improvement of 125m on six-minute walk test
  • Amelioration of pain in 6 of 7 patients experiencing pain at baseline  

"We are encouraged by these preliminary results. Improvements were seen in objective measures of muscle strength, agility and pain. These were accompanied by histomorphometric, radiologic and biomarker improvements, suggesting an integrated improvement of this debilitating skeletal disorder," said Hal Landy, MD, Chief Medical Officer at Enobia. "With nearly 50 patients on ENB-0040 treatment, we are rapidly expanding our understanding of the potential safety and efficacy of ENB-0040."  

Dr. Michael Whyte, Medical/Scientific Director of the Center for Metabolic Bone Disease and Molecular Research at Shriners Hospital for Children in St. Louis and a Principal Investigators said, "The findings from this study represent an important advance in o
'/>"/>

SOURCE Enobia Pharma Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Enobia Pharma Initiates Clinical Testing of Enzyme Replacement Therapy to Treat Hypophosphatasia
2. Enobia Pharma Receives FDA Orphan Drug Designation for Hypophosphatasia Product Candidate ENB-0040
3. Enobia Pharma Appoints Industry Veterans with Commercial and Manufacturing Expertise to Expand Senior Management Team
4. Enobia Initiates Infantile Enzyme Replacement Trial for Rare Bone Disease
5. Enobia Announces Positive Clinical Results With ENB-0040, a Bone Targeted Enzyme Replacement Therapy for Hypophosphatasia
6. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
7. Spherix Reports Second Quarter Earnings
8. Tapestry Reports Second Quarter 2007 Results
9. Callisto Reports on Second-Quarter 2007 Milestones
10. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
11. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... Research and Markets has announced the addition ... Reagent, by Application - Global Forecast to 2018" ... http://photos.prnewswire.com/prnh/20130307/600769 Biopharmaceuticals are pharmaceutical products isolated ... most important and widely used techniques for biopharmaceutical production. ... cell culture market in 2013. Growth in the biopharmaceutical ...
(Date:7/22/2014)... According to a new ... (Technology Types - Near infrared (NIR) spectroscopy, Raman spectroscopy and ... Size, Share, Growth, Trends and Forecast, 2013 - 2019," the ... is expected to grow at a CAGR of 7.4% from ... was the largest contributor to global process spectroscopy market ...
(Date:7/22/2014)... 2014 BiologicTx ® today announced their ... Kidney Paired Donation transplant exchange utilizing BiologicTx,s proprietary matching ... 9 at the Miami Transplant Institute, located at Jackson ... Kidney Paired Donation (KPD) is an ... kidney transplant with one another due to incompatible blood ...
Breaking Medicine Technology:Global Cell Culture (Bioreactor, Incubator, Centrifuge) Market - Forecast to 2018 2Global Cell Culture (Bioreactor, Incubator, Centrifuge) Market - Forecast to 2018 3Process Spectroscopy Market Expected to Reach USD 1,179.6 Million in 2019: Transparency Market Research 2Process Spectroscopy Market Expected to Reach USD 1,179.6 Million in 2019: Transparency Market Research 3Process Spectroscopy Market Expected to Reach USD 1,179.6 Million in 2019: Transparency Market Research 4BiologicTx Paired Donation Aids In Successful Kidney Transplants 2BiologicTx Paired Donation Aids In Successful Kidney Transplants 3
... July 12, 2011 Sevocity, the leader in ... v11.1 has achieved full certification through the Certification ... a CCHIT Certified® 2011 Ambulatory EHR.  Sevocity v11.1 ... the highest level awarded by CCHIT.  The Certification ...
... 12, 2011 ,   ... are,pleased to announce that they have been engaged ... apricitabine (ATC), a late-stage,novel treatment for HIV infection. ... the,healthcare and investment business sectors. Dr ...
Cached Medicine Technology:Sevocity Division of Conceptual MindWorks Inc.'s Sevocity EHR Earns CCHIT 2011 Certification 2PharmaVentures Engaged by Avexa to Assist in the Out-licensing of Apricitabine 2
(Date:7/22/2014)... July 22, 2014 SIMpalm, ... updated payment app for Forte Payment System. Forte Mobile ... ACH payments on iPhone, iPod and iPad. The ... been recently updated by SIMpalm. This update was for ... currently supported on iOS 4.3 and is available to ...
(Date:7/22/2014)... treatment and cardiovascular risk assessment state that men have ... cardiovascular disease or of having a heart attack or ... (based on age, smoking history, and cholesterol and blood ... and how aggressively to treat high cholesterol are examined ... , a peer-reviewed publication from Mary Ann Liebert, Inc., ...
(Date:7/22/2014)... July 22, 2014 The Beryl Institute ... third annual Institute Scholar Program. These offerings reinforce the ... patient experience in healthcare and the need for rigorous ... grant and scholar programs are intended to ... Value of focusing on the patient experience before, ...
(Date:7/22/2014)... NY (PRWEB) July 22, 2014 ... ( http://www.risperdallawsuitcenter.com/ ) in the Philadelphia ... to deny punitive damages in cases alleging the ... growth), Bernstein Liebhard LLP reports. In an Order ... denied a plaintiffs’ request to certify the matter ...
(Date:7/22/2014)... 22, 2014 The park is the ... Kendalltown Homeowners Association, Inc., made a recent ... community with the purchase of playground equipment from American ... in beautiful Miami Florida, and is a 475-unit community ... the surrounding landscape has created a tropical paradise with ...
Breaking Medicine News(10 mins):Health News:SIMpalm Launched Updated Forte Mobile Payment App on iPhone and iPad for Its Client 2Health News:SIMpalm Launched Updated Forte Mobile Payment App on iPhone and iPad for Its Client 3Health News:The Beryl Institute Opens Applications for 2014 Patient Experience Grant and Scholar Programs 2Health News:The Beryl Institute Opens Applications for 2014 Patient Experience Grant and Scholar Programs 3Health News:Risperdal Lawsuit News: Pennsylvania Judge Won’t Reconsider Denial of Punitive Damages for Risperdal Gynecomastia Plaintiffs, Bernstein Liebhard LLP Reports 2Health News:Risperdal Lawsuit News: Pennsylvania Judge Won’t Reconsider Denial of Punitive Damages for Risperdal Gynecomastia Plaintiffs, Bernstein Liebhard LLP Reports 3Health News:Risperdal Lawsuit News: Pennsylvania Judge Won’t Reconsider Denial of Punitive Damages for Risperdal Gynecomastia Plaintiffs, Bernstein Liebhard LLP Reports 4Health News:Fun in the Florida Sun: Kendalltown Homeowners Association Inc. Expands Outdoor Recreation with American Parks Company™ 2Health News:Fun in the Florida Sun: Kendalltown Homeowners Association Inc. Expands Outdoor Recreation with American Parks Company™ 3
... , , , , ... leading provider of specialty healthcare solutions, unveiled its new corporate headquarters in ... County and New York State. , , (Logo: ... APS Healthcare, which operates 41 Medicaid programs in 26 states and Puerto ...
... Contest ... ... -- InSound Medical , manufacturer and developer of Lyric®, the first 100 percent invisible, ... Lyric Hearing Story" Contest. Lyric wearers have the opportunity to win a free year ...
... ... economy, small business owners and stockholders, agree on ten crucial issues at the center of ... O,Leary Report. , ... (Vocus) September 15, 2009 -- Two groups that drive the American economy, small business owners ...
... PALO ALTO, Calif., Sept. 15 Telik, Inc. (Nasdaq: ... overview at the UBS Global Life Sciences Conference in New York ... (8:30 a.m. Pacific time). A live and archived webcast of ... , Telik, Inc. of Palo Alto, CA, is ...
... , LOS ANGELES, Sept. 15 Illustrating ... Cruises is introducing aboard its ships Nordic Walking, fitness walking ... LEKI USA, a leading manufacturer of skiing, trekking and Nordic ... options at sea. Specifically designed to engage the entire ...
... , ST. LOUIS, Sept. 15 KV Pharmaceutical ... the Company received an action by written consent of stockholders ... of certain amendments to the Company,s By-Laws (the "Proposed Amendments"). ... Amendments, is attached as Exhibit 99.1 to the ...
Cached Medicine News:Health News:APS Healthcare Unveils New Corporate Headquarters in White Plains, Bringing 200 New Jobs, With Help From New York and Westchester 2Health News:APS Healthcare Unveils New Corporate Headquarters in White Plains, Bringing 200 New Jobs, With Help From New York and Westchester 3Health News:InSound Medical Kicks Off "Tell Us Your Story" Contest 2Health News:Small Business Owners and Stockholders Agree on Ten Crucial Health Care Reform Issues, According to New Zogby/O'Leary Poll 2Health News:Small Business Owners and Stockholders Agree on Ten Crucial Health Care Reform Issues, According to New Zogby/O'Leary Poll 3Health News:Small Business Owners and Stockholders Agree on Ten Crucial Health Care Reform Issues, According to New Zogby/O'Leary Poll 4Health News:New Nordic Poles Help Crystal Guests Explore New Terrain at Sea 2Health News:KV Pharmaceutical Receives Stockholder Action by Written Consent 2Health News:KV Pharmaceutical Receives Stockholder Action by Written Consent 3Health News:KV Pharmaceutical Receives Stockholder Action by Written Consent 4Health News:KV Pharmaceutical Receives Stockholder Action by Written Consent 5Health News:KV Pharmaceutical Receives Stockholder Action by Written Consent 6
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: